Replies to post #5 on Biosyent Inc (RX)

[bbotcs]

Markets of $2-$5M are pretty small. This suggests to me that they will need to acquire a lot of licenses, which means profit margins lower than they would be with a few higher-revenue drugs because of the additional costs of selling (and housing) lots of drugs.

This isn't going to be an easy ride, imo.

[FrankLind]

Since this strategy is much lower risk, and seems to lead to huge ROI, why aren't so many other companies doing this?

What is Biosyent's competitive advantage in finding and then signing on these opportunities?

[btmfdr2]

This is more than a 10 bagger from where I started buying a couple of years ago. I remember buying ten thousand and fifteen thousand shares at a time at .26. Wish I still had the 280K shares I had a year ago. Oh well.

Thanks so much Zenlunatic!